These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 29044860)

  • 1. Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.
    Busch RS; Ruggles J; Han J; Hardy E
    Int J Clin Pract; 2017 Dec; 71(12):. PubMed ID: 29044860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.
    Trautmann ME; Van Gaal L; Han J; Hardy E
    J Diabetes Complications; 2017 Sep; 31(9):1415-1422. PubMed ID: 28669463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
    Trautmann ME; Han J; Ruggles J
    Clin Ther; 2016 Jun; 38(6):1464-1473. PubMed ID: 27126504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
    Matyjaszek-Matuszek B; Lenart-Lipińska M; Rogalska D; Nowakowski A;
    Endokrynol Pol; 2013; 64(5):375-82. PubMed ID: 24186595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
    Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
    Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
    Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.
    Shaw JE; Gallwitz B; Han J; Hardy E; Schernthaner G
    Diabetes Obes Metab; 2017 Dec; 19(12):1793-1797. PubMed ID: 28573708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis.
    Sheu WH; Brunell SC; Blase E
    Diabetes Res Clin Pract; 2016 Apr; 114():160-72. PubMed ID: 26827116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
    McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
    Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
    Scott DA; Boye KS; Timlin L; Clark JF; Best JH
    Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
    Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
    Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
    Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I
    Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.
    McCormack PL
    Drugs; 2014 Mar; 74(3):325-51. PubMed ID: 24435322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
    Lecube A; Bueno M; Suárez X
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.